 Paco Herson
Concepts (480)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Ischemia | 34 | 2023 | 297 | 10.410 |
Why?
| | Heart Arrest | 23 | 2021 | 289 | 5.600 |
Why?
| | TRPM Cation Channels | 11 | 2021 | 67 | 4.800 |
Why?
| | Hippocampus | 21 | 2023 | 697 | 3.560 |
Why?
| | Neurons | 31 | 2023 | 1285 | 3.520 |
Why?
| | Stroke | 20 | 2023 | 1015 | 3.510 |
Why?
| | Neuroprotective Agents | 16 | 2020 | 105 | 3.310 |
Why?
| | Cardiopulmonary Resuscitation | 15 | 2021 | 220 | 2.970 |
Why?
| | Sex Characteristics | 14 | 2023 | 639 | 2.510 |
Why?
| | Cell Death | 16 | 2021 | 324 | 2.220 |
Why?
| | Purkinje Cells | 7 | 2019 | 66 | 2.170 |
Why?
| | Mice, Inbred C57BL | 45 | 2021 | 4718 | 1.750 |
Why?
| | Recovery of Function | 5 | 2021 | 577 | 1.720 |
Why?
| | Animals | 93 | 2023 | 31884 | 1.500 |
Why?
| | CA1 Region, Hippocampal | 6 | 2019 | 29 | 1.500 |
Why?
| | Mice | 61 | 2023 | 14934 | 1.460 |
Why?
| | Androgens | 8 | 2014 | 167 | 1.430 |
Why?
| | Long-Term Potentiation | 7 | 2019 | 145 | 1.300 |
Why?
| | Ischemia | 5 | 2022 | 363 | 1.270 |
Why?
| | Disease Models, Animal | 24 | 2022 | 3547 | 1.270 |
Why?
| | Gonadal Steroid Hormones | 4 | 2018 | 124 | 1.240 |
Why?
| | Neuroprotection | 3 | 2020 | 30 | 1.230 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 6 | 2023 | 158 | 1.170 |
Why?
| | Peptide Fragments | 2 | 2021 | 668 | 1.100 |
Why?
| | Receptors, GABA-A | 4 | 2021 | 82 | 1.030 |
Why?
| | Infarction, Middle Cerebral Artery | 12 | 2023 | 38 | 1.020 |
Why?
| | Poly(ADP-ribose) Polymerases | 4 | 2013 | 88 | 0.990 |
Why?
| | Reperfusion Injury | 8 | 2020 | 254 | 0.970 |
Why?
| | Hypothermia, Induced | 3 | 2016 | 69 | 0.960 |
Why?
| | Male | 66 | 2023 | 55814 | 0.910 |
Why?
| | Small-Conductance Calcium-Activated Potassium Channels | 4 | 2014 | 8 | 0.890 |
Why?
| | Calcium | 10 | 2022 | 1104 | 0.890 |
Why?
| | Brain Injuries, Traumatic | 4 | 2023 | 301 | 0.870 |
Why?
| | Thrombosis | 3 | 2022 | 302 | 0.810 |
Why?
| | Brain Injuries | 5 | 2021 | 452 | 0.810 |
Why?
| | Cognition | 3 | 2019 | 982 | 0.780 |
Why?
| | Patch-Clamp Techniques | 13 | 2019 | 241 | 0.770 |
Why?
| | Neuronal Plasticity | 8 | 2023 | 209 | 0.740 |
Why?
| | Signal Transduction | 10 | 2021 | 4527 | 0.740 |
Why?
| | Brain | 12 | 2022 | 2378 | 0.730 |
Why?
| | Excitatory Postsynaptic Potentials | 3 | 2016 | 99 | 0.730 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 4 | 2020 | 181 | 0.720 |
Why?
| | Cerebellum | 4 | 2011 | 200 | 0.700 |
Why?
| | Pregnanolone | 2 | 2011 | 20 | 0.700 |
Why?
| | Sex Factors | 9 | 2018 | 1722 | 0.690 |
Why?
| | Estradiol | 5 | 2018 | 455 | 0.680 |
Why?
| | Brain-Derived Neurotrophic Factor | 4 | 2019 | 106 | 0.680 |
Why?
| | Nogo Proteins | 1 | 2019 | 10 | 0.660 |
Why?
| | Potassium Channels | 7 | 2003 | 121 | 0.630 |
Why?
| | Cognitive Dysfunction | 2 | 2019 | 273 | 0.620 |
Why?
| | Adult Stem Cells | 1 | 2018 | 32 | 0.600 |
Why?
| | Nerve Regeneration | 1 | 2018 | 53 | 0.600 |
Why?
| | Guideline Adherence | 1 | 2022 | 492 | 0.590 |
Why?
| | Long-Term Synaptic Depression | 2 | 2018 | 48 | 0.570 |
Why?
| | Estrogens | 5 | 2013 | 317 | 0.570 |
Why?
| | Mice, Knockout | 11 | 2021 | 2586 | 0.560 |
Why?
| | Neurogenesis | 1 | 2018 | 102 | 0.560 |
Why?
| | Neural Stem Cells | 1 | 2018 | 115 | 0.560 |
Why?
| | Female | 40 | 2023 | 59720 | 0.550 |
Why?
| | Nervous System Diseases | 1 | 2019 | 253 | 0.550 |
Why?
| | Aging | 3 | 2019 | 1624 | 0.550 |
Why?
| | Clotrimazole | 2 | 2013 | 2 | 0.530 |
Why?
| | Microglia | 5 | 2018 | 202 | 0.530 |
Why?
| | Sirtuin 2 | 1 | 2015 | 12 | 0.520 |
Why?
| | Membrane Glycoproteins | 1 | 2018 | 429 | 0.520 |
Why?
| | Oxygen | 4 | 2012 | 855 | 0.500 |
Why?
| | Cell Culture Techniques | 3 | 2013 | 344 | 0.480 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2018 | 396 | 0.480 |
Why?
| | Emergency Medical Services | 1 | 2022 | 587 | 0.480 |
Why?
| | Cell Hypoxia | 4 | 2013 | 220 | 0.470 |
Why?
| | Tissue Plasminogen Activator | 3 | 2022 | 227 | 0.460 |
Why?
| | Animal Experimentation | 1 | 2014 | 6 | 0.460 |
Why?
| | Naltrexone | 1 | 2015 | 83 | 0.460 |
Why?
| | Inhibitory Postsynaptic Potentials | 2 | 2011 | 28 | 0.460 |
Why?
| | Rats | 18 | 2023 | 4980 | 0.450 |
Why?
| | Models, Animal | 2 | 2013 | 349 | 0.450 |
Why?
| | Cerebral Cortex | 3 | 2021 | 381 | 0.430 |
Why?
| | Potassium Channels, Voltage-Gated | 2 | 2003 | 48 | 0.420 |
Why?
| | Peptides | 3 | 2023 | 849 | 0.420 |
Why?
| | Ion Channels | 4 | 2004 | 124 | 0.410 |
Why?
| | Neural Inhibition | 2 | 2011 | 144 | 0.400 |
Why?
| | Synapses | 4 | 2021 | 330 | 0.380 |
Why?
| | Magnetic Fields | 3 | 2022 | 22 | 0.380 |
Why?
| | Oxidative Stress | 7 | 2020 | 1086 | 0.360 |
Why?
| | Calcium Channels, T-Type | 2 | 2022 | 16 | 0.360 |
Why?
| | Memory | 3 | 2023 | 209 | 0.360 |
Why?
| | Hydrogen Peroxide | 4 | 2020 | 287 | 0.360 |
Why?
| | Progesterone | 3 | 2010 | 232 | 0.340 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 3 | 2014 | 24 | 0.340 |
Why?
| | Age Factors | 5 | 2021 | 2900 | 0.340 |
Why?
| | Dexmedetomidine | 3 | 2014 | 45 | 0.330 |
Why?
| | Rats, Sprague-Dawley | 9 | 2023 | 2216 | 0.330 |
Why?
| | Drug Delivery Systems | 2 | 2022 | 296 | 0.330 |
Why?
| | Cells, Cultured | 10 | 2018 | 3897 | 0.320 |
Why?
| | Glucose | 7 | 2014 | 900 | 0.320 |
Why?
| | Immunohistochemistry | 7 | 2016 | 1635 | 0.320 |
Why?
| | Ion Channel Gating | 6 | 2004 | 83 | 0.310 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2014 | 965 | 0.310 |
Why?
| | Cerebrovascular Disorders | 1 | 2009 | 83 | 0.310 |
Why?
| | Action Potentials | 6 | 2022 | 406 | 0.310 |
Why?
| | Sepsis | 3 | 2019 | 508 | 0.310 |
Why?
| | NAD | 2 | 1999 | 64 | 0.300 |
Why?
| | HEK293 Cells | 3 | 2020 | 590 | 0.300 |
Why?
| | Memory Disorders | 2 | 2019 | 154 | 0.290 |
Why?
| | Humans | 32 | 2023 | 115222 | 0.290 |
Why?
| | Brain Infarction | 3 | 2016 | 22 | 0.280 |
Why?
| | Colloids | 2 | 2017 | 56 | 0.270 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2019 | 1860 | 0.270 |
Why?
| | Dihydrotestosterone | 5 | 2013 | 39 | 0.260 |
Why?
| | Time Factors | 11 | 2017 | 6157 | 0.260 |
Why?
| | Protective Agents | 2 | 2019 | 38 | 0.250 |
Why?
| | Military Personnel | 2 | 2023 | 523 | 0.230 |
Why?
| | Paraplegia | 2 | 2015 | 52 | 0.230 |
Why?
| | Myelin Proteins | 3 | 2016 | 45 | 0.220 |
Why?
| | Epoxide Hydrolases | 2 | 2013 | 10 | 0.220 |
Why?
| | Receptors, Adrenergic, alpha-2 | 2 | 2013 | 15 | 0.220 |
Why?
| | Calmodulin | 2 | 2019 | 71 | 0.220 |
Why?
| | Oxidants | 2 | 2020 | 112 | 0.220 |
Why?
| | Olfactory Receptor Neurons | 1 | 2004 | 67 | 0.220 |
Why?
| | Glycosaminoglycans | 1 | 2023 | 79 | 0.220 |
Why?
| | Spinocerebellar Degenerations | 1 | 2003 | 5 | 0.220 |
Why?
| | Smell | 1 | 2004 | 112 | 0.220 |
Why?
| | Corpus Striatum | 4 | 2016 | 125 | 0.220 |
Why?
| | Pneumonia | 2 | 2021 | 569 | 0.220 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 2 | 2013 | 40 | 0.220 |
Why?
| | Aspartic Acid Endopeptidases | 1 | 2023 | 21 | 0.220 |
Why?
| | Blood-Brain Barrier | 2 | 2022 | 106 | 0.220 |
Why?
| | Orchiectomy | 3 | 2013 | 57 | 0.210 |
Why?
| | Behavior, Animal | 3 | 2018 | 462 | 0.210 |
Why?
| | Amyloid beta-Protein Precursor | 1 | 2023 | 54 | 0.210 |
Why?
| | Spinal Cord | 3 | 2014 | 349 | 0.210 |
Why?
| | Spinal Cord Ischemia | 2 | 2013 | 63 | 0.210 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2023 | 71 | 0.210 |
Why?
| | Primary Cell Culture | 2 | 2013 | 149 | 0.200 |
Why?
| | Myelin Sheath | 3 | 2023 | 145 | 0.200 |
Why?
| | Cerebral Infarction | 1 | 2022 | 39 | 0.200 |
Why?
| | Heparitin Sulfate | 2 | 2019 | 39 | 0.200 |
Why?
| | Emergency Medical Dispatch | 1 | 2022 | 6 | 0.200 |
Why?
| | Phosphorylation | 4 | 2023 | 1574 | 0.200 |
Why?
| | Spinal Cord Injuries | 2 | 2015 | 174 | 0.200 |
Why?
| | Benzimidazoles | 2 | 2014 | 137 | 0.200 |
Why?
| | Receptors, Androgen | 3 | 2013 | 131 | 0.200 |
Why?
| | Information Systems | 1 | 2022 | 61 | 0.200 |
Why?
| | Plasminogen | 1 | 2021 | 32 | 0.200 |
Why?
| | Heroin | 1 | 2021 | 23 | 0.190 |
Why?
| | Presynaptic Terminals | 1 | 2021 | 55 | 0.190 |
Why?
| | Organ Culture Techniques | 1 | 2021 | 141 | 0.190 |
Why?
| | Islets of Langerhans | 2 | 1997 | 729 | 0.190 |
Why?
| | Cell Survival | 6 | 2020 | 1022 | 0.190 |
Why?
| | gamma-Aminobutyric Acid | 2 | 2017 | 144 | 0.190 |
Why?
| | Blotting, Western | 5 | 2012 | 1150 | 0.190 |
Why?
| | Encephalitis | 2 | 2014 | 127 | 0.190 |
Why?
| | Eclampsia | 1 | 2020 | 4 | 0.190 |
Why?
| | Thalamus | 1 | 2021 | 75 | 0.180 |
Why?
| | Extinction, Psychological | 1 | 2021 | 78 | 0.180 |
Why?
| | Insulin | 3 | 1999 | 2083 | 0.180 |
Why?
| | Insulinoma | 2 | 1997 | 29 | 0.180 |
Why?
| | Amyloid beta-Peptides | 1 | 2023 | 189 | 0.180 |
Why?
| | Cell-Derived Microparticles | 1 | 2021 | 58 | 0.180 |
Why?
| | Adaptation, Physiological | 1 | 2004 | 481 | 0.180 |
Why?
| | Extracellular Vesicles | 1 | 2021 | 83 | 0.180 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2020 | 37 | 0.170 |
Why?
| | Death-Associated Protein Kinases | 1 | 2020 | 10 | 0.170 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 20 | 0.170 |
Why?
| | Cell Membrane | 2 | 2003 | 681 | 0.170 |
Why?
| | rho GTP-Binding Proteins | 1 | 2020 | 61 | 0.170 |
Why?
| | Inhibitory Concentration 50 | 1 | 2019 | 75 | 0.170 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2010 | 928 | 0.170 |
Why?
| | Fibrinolysis | 2 | 2021 | 160 | 0.170 |
Why?
| | Intravital Microscopy | 1 | 2019 | 23 | 0.170 |
Why?
| | Fibrinolytic Agents | 1 | 2022 | 233 | 0.170 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2019 | 61 | 0.170 |
Why?
| | Optical Imaging | 1 | 2019 | 54 | 0.170 |
Why?
| | Potassium Channels, Calcium-Activated | 3 | 2004 | 9 | 0.170 |
Why?
| | Axons | 2 | 2018 | 179 | 0.160 |
Why?
| | Models, Theoretical | 1 | 2023 | 517 | 0.160 |
Why?
| | Oligosaccharides | 1 | 2019 | 46 | 0.160 |
Why?
| | Mutagenesis | 1 | 2019 | 170 | 0.160 |
Why?
| | Cofilin 1 | 1 | 2018 | 5 | 0.160 |
Why?
| | Nerve Net | 1 | 2021 | 225 | 0.160 |
Why?
| | Drug Design | 1 | 2019 | 151 | 0.160 |
Why?
| | Calcineurin | 1 | 2019 | 89 | 0.160 |
Why?
| | Protein Aggregation, Pathological | 1 | 2018 | 14 | 0.160 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 503 | 0.160 |
Why?
| | Pre-Eclampsia | 1 | 2020 | 165 | 0.160 |
Why?
| | Mice, Transgenic | 5 | 2016 | 1956 | 0.150 |
Why?
| | Holoenzymes | 1 | 2018 | 21 | 0.150 |
Why?
| | Thalamic Nuclei | 1 | 2018 | 8 | 0.150 |
Why?
| | Mitochondria | 2 | 2021 | 750 | 0.150 |
Why?
| | Membrane Proteins | 2 | 2021 | 1019 | 0.150 |
Why?
| | Lateral Ventricles | 1 | 2018 | 24 | 0.150 |
Why?
| | Interleukin-10 | 3 | 2015 | 297 | 0.150 |
Why?
| | Molecular Dynamics Simulation | 1 | 2019 | 201 | 0.150 |
Why?
| | Dementia | 1 | 2020 | 186 | 0.150 |
Why?
| | Heparin | 1 | 2019 | 222 | 0.150 |
Why?
| | Myelin Proteolipid Protein | 1 | 2018 | 61 | 0.150 |
Why?
| | Intracranial Arterial Diseases | 1 | 2017 | 6 | 0.150 |
Why?
| | Alloxan | 1 | 1997 | 4 | 0.150 |
Why?
| | Receptors, AMPA | 2 | 2018 | 120 | 0.140 |
Why?
| | Glutathione | 1 | 1999 | 302 | 0.140 |
Why?
| | Receptors, Glutamate | 1 | 2016 | 18 | 0.140 |
Why?
| | Cerebral Arteries | 1 | 2017 | 56 | 0.140 |
Why?
| | Inflammation | 4 | 2021 | 2485 | 0.140 |
Why?
| | Gene Knockdown Techniques | 2 | 2020 | 299 | 0.140 |
Why?
| | Leukoencephalopathies | 1 | 2016 | 21 | 0.130 |
Why?
| | Actins | 1 | 2018 | 383 | 0.130 |
Why?
| | Pericytes | 1 | 2016 | 24 | 0.130 |
Why?
| | Spleen | 3 | 2015 | 486 | 0.130 |
Why?
| | Cations | 3 | 2003 | 79 | 0.130 |
Why?
| | Brain Concussion | 1 | 2023 | 469 | 0.130 |
Why?
| | Cell Communication | 2 | 2016 | 280 | 0.130 |
Why?
| | Collagen Type I | 1 | 2016 | 108 | 0.130 |
Why?
| | Furans | 1 | 2015 | 22 | 0.130 |
Why?
| | Tretinoin | 1 | 2016 | 124 | 0.130 |
Why?
| | Transfection | 2 | 2016 | 872 | 0.130 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2013 | 315 | 0.130 |
Why?
| | Membrane Potentials | 5 | 1999 | 249 | 0.130 |
Why?
| | Arginase | 1 | 2015 | 27 | 0.120 |
Why?
| | Mutation | 2 | 2020 | 3350 | 0.120 |
Why?
| | Magnetic Resonance Angiography | 1 | 2017 | 240 | 0.120 |
Why?
| | Calbindins | 1 | 2014 | 5 | 0.120 |
Why?
| | Interleukin-1beta | 2 | 2014 | 370 | 0.120 |
Why?
| | Dizocilpine Maleate | 1 | 2014 | 14 | 0.120 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2014 | 30 | 0.120 |
Why?
| | Neutrophil Activation | 1 | 2015 | 94 | 0.120 |
Why?
| | Calcium Channel Agonists | 1 | 2014 | 10 | 0.120 |
Why?
| | Quinolines | 1 | 2015 | 129 | 0.120 |
Why?
| | Trauma, Nervous System | 1 | 2014 | 2 | 0.120 |
Why?
| | Tissue Culture Techniques | 1 | 2014 | 66 | 0.120 |
Why?
| | Electroencephalography | 1 | 2016 | 362 | 0.120 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2014 | 87 | 0.120 |
Why?
| | Nerve Tissue Proteins | 2 | 2016 | 531 | 0.120 |
Why?
| | Microinjections | 2 | 2011 | 77 | 0.120 |
Why?
| | Lentivirus | 2 | 2011 | 45 | 0.120 |
Why?
| | Practice Guidelines as Topic | 1 | 2022 | 1397 | 0.120 |
Why?
| | Cross Infection | 1 | 2016 | 199 | 0.120 |
Why?
| | Toll-Like Receptor 4 | 2 | 2013 | 286 | 0.120 |
Why?
| | Analysis of Variance | 3 | 2015 | 1231 | 0.110 |
Why?
| | CD40 Antigens | 1 | 2014 | 82 | 0.110 |
Why?
| | Aortic Diseases | 1 | 2015 | 110 | 0.110 |
Why?
| | Immunophenotyping | 1 | 2014 | 276 | 0.110 |
Why?
| | Body Temperature | 1 | 2014 | 210 | 0.110 |
Why?
| | Arachidonic Acids | 1 | 2013 | 58 | 0.110 |
Why?
| | Piperidines | 1 | 2014 | 162 | 0.110 |
Why?
| | Immune Tolerance | 1 | 2015 | 329 | 0.110 |
Why?
| | Embryo, Mammalian | 1 | 2013 | 214 | 0.110 |
Why?
| | bcl-2-Associated X Protein | 1 | 2013 | 45 | 0.110 |
Why?
| | Testosterone | 3 | 2010 | 343 | 0.100 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2013 | 184 | 0.100 |
Why?
| | Polymerase Chain Reaction | 3 | 2012 | 1000 | 0.100 |
Why?
| | Glomerular Filtration Barrier | 1 | 2012 | 1 | 0.100 |
Why?
| | RNA, Small Interfering | 2 | 2011 | 541 | 0.100 |
Why?
| | Treatment Outcome | 3 | 2022 | 9151 | 0.100 |
Why?
| | Retrospective Studies | 7 | 2023 | 12597 | 0.100 |
Why?
| | Endothelium | 1 | 2012 | 112 | 0.100 |
Why?
| | Microscopy, Immunoelectron | 1 | 2011 | 43 | 0.100 |
Why?
| | United States | 3 | 2023 | 12256 | 0.100 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2011 | 50 | 0.090 |
Why?
| | Pyramidal Cells | 1 | 2011 | 50 | 0.090 |
Why?
| | Child | 4 | 2019 | 18468 | 0.090 |
Why?
| | Culture Media | 1 | 2011 | 155 | 0.090 |
Why?
| | Acute Lung Injury | 1 | 2014 | 300 | 0.090 |
Why?
| | Iraq War, 2003-2011 | 2 | 2023 | 151 | 0.090 |
Why?
| | Isoflurane | 1 | 2010 | 8 | 0.090 |
Why?
| | Afghan Campaign 2001- | 2 | 2023 | 162 | 0.090 |
Why?
| | Anesthetics, Inhalation | 1 | 2010 | 14 | 0.090 |
Why?
| | Disease Progression | 1 | 2017 | 2390 | 0.090 |
Why?
| | RNA, Messenger | 4 | 2018 | 2563 | 0.090 |
Why?
| | Cell Movement | 1 | 2014 | 866 | 0.090 |
Why?
| | Genetic Vectors | 1 | 2011 | 291 | 0.090 |
Why?
| | Cell Line | 5 | 2012 | 2645 | 0.090 |
Why?
| | Neutrophils | 1 | 2015 | 1163 | 0.080 |
Why?
| | Recombinant Fusion Proteins | 2 | 2011 | 616 | 0.080 |
Why?
| | Motor Activity | 2 | 2011 | 643 | 0.080 |
Why?
| | Ischemic Attack, Transient | 1 | 2010 | 61 | 0.080 |
Why?
| | In Vitro Techniques | 1 | 2011 | 1036 | 0.080 |
Why?
| | Pregnancy | 3 | 2020 | 5525 | 0.080 |
Why?
| | Aged | 3 | 2022 | 19136 | 0.080 |
Why?
| | Oligodendroglia | 2 | 2023 | 148 | 0.080 |
Why?
| | Kidney | 2 | 2012 | 1188 | 0.080 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2013 | 799 | 0.070 |
Why?
| | Animals, Newborn | 2 | 2023 | 779 | 0.070 |
Why?
| | Acute Kidney Injury | 1 | 2014 | 639 | 0.070 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2011 | 629 | 0.070 |
Why?
| | Apoptosis | 3 | 2016 | 2368 | 0.070 |
Why?
| | Menopause | 1 | 2010 | 271 | 0.070 |
Why?
| | In Situ Nick-End Labeling | 1 | 2006 | 119 | 0.070 |
Why?
| | Biomarkers | 1 | 2016 | 3422 | 0.070 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 26 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2010 | 351 | 0.070 |
Why?
| | B-Lymphocytes | 1 | 2011 | 772 | 0.070 |
Why?
| | Tumor Cells, Cultured | 2 | 1997 | 851 | 0.060 |
Why?
| | Hospital Mortality | 2 | 2021 | 776 | 0.060 |
Why?
| | Cyclic Nucleotide-Gated Cation Channels | 1 | 2004 | 21 | 0.060 |
Why?
| | Electrophysiology | 3 | 2003 | 201 | 0.060 |
Why?
| | Decorin | 1 | 2023 | 6 | 0.060 |
Why?
| | Databases, Factual | 2 | 2021 | 1136 | 0.060 |
Why?
| | Infarction | 1 | 2023 | 12 | 0.060 |
Why?
| | Chondroitin Sulfates | 1 | 2023 | 33 | 0.060 |
Why?
| | Cyclic AMP | 1 | 2004 | 226 | 0.060 |
Why?
| | Kv1.1 Potassium Channel | 1 | 2003 | 7 | 0.050 |
Why?
| | Genes, Lethal | 1 | 2003 | 26 | 0.050 |
Why?
| | Rats, Wistar | 2 | 2017 | 369 | 0.050 |
Why?
| | Carbonic Anhydrases | 1 | 2003 | 13 | 0.050 |
Why?
| | Shal Potassium Channels | 1 | 2003 | 6 | 0.050 |
Why?
| | Acetazolamide | 1 | 2003 | 31 | 0.050 |
Why?
| | Spatial Memory | 1 | 2022 | 17 | 0.050 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 126 | 0.050 |
Why?
| | Iraq | 1 | 2023 | 81 | 0.050 |
Why?
| | Models, Neurological | 1 | 2004 | 212 | 0.050 |
Why?
| | Afghanistan | 1 | 2023 | 108 | 0.050 |
Why?
| | Tolbutamide | 2 | 1999 | 5 | 0.050 |
Why?
| | Hypnotics and Sedatives | 1 | 2023 | 134 | 0.050 |
Why?
| | Fibrin Clot Lysis Time | 1 | 2021 | 8 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2014 | 401 | 0.050 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 2 | 2011 | 43 | 0.050 |
Why?
| | Synaptic Transmission | 1 | 2003 | 228 | 0.050 |
Why?
| | Self Administration | 1 | 2021 | 123 | 0.050 |
Why?
| | Adoptive Transfer | 2 | 2011 | 198 | 0.050 |
Why?
| | Aorta, Thoracic | 2 | 2013 | 261 | 0.050 |
Why?
| | Ovariectomy | 2 | 2012 | 117 | 0.050 |
Why?
| | Swine | 1 | 2023 | 705 | 0.050 |
Why?
| | Tumor Necrosis Factors | 1 | 2020 | 9 | 0.040 |
Why?
| | Inflammation Mediators | 2 | 2013 | 476 | 0.040 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2001 | 185 | 0.040 |
Why?
| | Neurotoxins | 1 | 2020 | 26 | 0.040 |
Why?
| | Nucleus Accumbens | 1 | 2021 | 124 | 0.040 |
Why?
| | Stress, Physiological | 1 | 2003 | 377 | 0.040 |
Why?
| | Up-Regulation | 1 | 2003 | 812 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2020 | 202 | 0.040 |
Why?
| | Risk Assessment | 2 | 2021 | 2981 | 0.040 |
Why?
| | Air Ambulances | 1 | 2020 | 34 | 0.040 |
Why?
| | Dendritic Spines | 1 | 2020 | 49 | 0.040 |
Why?
| | Thapsigargin | 1 | 1999 | 18 | 0.040 |
Why?
| | Cesium | 1 | 1999 | 16 | 0.040 |
Why?
| | Ion Transport | 1 | 1999 | 55 | 0.040 |
Why?
| | Lymph Nodes | 2 | 2011 | 422 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2003 | 1133 | 0.040 |
Why?
| | Recurrence | 1 | 2021 | 952 | 0.040 |
Why?
| | Glutamic Acid | 1 | 2020 | 211 | 0.040 |
Why?
| | Oligodendrocyte Precursor Cells | 1 | 2018 | 18 | 0.040 |
Why?
| | Barium | 1 | 1997 | 25 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2021 | 6358 | 0.040 |
Why?
| | Seizures | 1 | 2020 | 341 | 0.040 |
Why?
| | Calcium Signaling | 1 | 2019 | 213 | 0.040 |
Why?
| | Adult | 2 | 2021 | 30711 | 0.040 |
Why?
| | Thiourea | 1 | 1997 | 39 | 0.040 |
Why?
| | Resuscitation | 1 | 2020 | 247 | 0.040 |
Why?
| | Hypoxia | 2 | 2014 | 959 | 0.040 |
Why?
| | Magnesium | 1 | 1997 | 145 | 0.040 |
Why?
| | Inpatients | 1 | 2021 | 378 | 0.040 |
Why?
| | Exons | 1 | 2018 | 301 | 0.040 |
Why?
| | Free Radical Scavengers | 1 | 1997 | 78 | 0.040 |
Why?
| | Oligopeptides | 1 | 1999 | 234 | 0.040 |
Why?
| | Kinetics | 2 | 1997 | 1558 | 0.040 |
Why?
| | Niacinamide | 1 | 1997 | 62 | 0.040 |
Why?
| | Protein Domains | 1 | 2018 | 207 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2018 | 339 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2018 | 271 | 0.030 |
Why?
| | Adolescent | 3 | 2021 | 17889 | 0.030 |
Why?
| | Protein Transport | 1 | 2018 | 398 | 0.030 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2016 | 42 | 0.030 |
Why?
| | Cytokines | 2 | 2014 | 1843 | 0.030 |
Why?
| | Heme Oxygenase-1 | 1 | 2016 | 52 | 0.030 |
Why?
| | Cell Polarity | 1 | 1997 | 131 | 0.030 |
Why?
| | Biological Transport | 1 | 2017 | 372 | 0.030 |
Why?
| | Mice, Inbred ICR | 1 | 2016 | 109 | 0.030 |
Why?
| | Glucose Transporter Type 1 | 1 | 2016 | 42 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 686 | 0.030 |
Why?
| | Glutathione Transferase | 1 | 2016 | 95 | 0.030 |
Why?
| | Cysteine | 1 | 1997 | 171 | 0.030 |
Why?
| | Stromal Cells | 1 | 2016 | 96 | 0.030 |
Why?
| | Estrogen Receptor alpha | 2 | 2010 | 121 | 0.030 |
Why?
| | Receptors, Estrogen | 2 | 2012 | 372 | 0.030 |
Why?
| | Functional Laterality | 1 | 2016 | 198 | 0.030 |
Why?
| | T-Lymphocytes | 2 | 2015 | 1748 | 0.030 |
Why?
| | Risk Factors | 2 | 2021 | 8658 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 1997 | 431 | 0.030 |
Why?
| | Pharmaceutical Preparations | 1 | 2017 | 169 | 0.030 |
Why?
| | California | 1 | 2016 | 364 | 0.030 |
Why?
| | Chronic Disease | 1 | 2021 | 1594 | 0.030 |
Why?
| | Neurologic Examination | 1 | 2015 | 115 | 0.030 |
Why?
| | Nanostructures | 1 | 2016 | 96 | 0.030 |
Why?
| | Blood Vessels | 1 | 2016 | 180 | 0.030 |
Why?
| | Hindlimb | 1 | 2015 | 130 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 1997 | 536 | 0.030 |
Why?
| | Locomotion | 1 | 2015 | 81 | 0.030 |
Why?
| | Protein Binding | 1 | 2020 | 1898 | 0.030 |
Why?
| | Hypoglycemic Agents | 2 | 1999 | 1006 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2014 | 165 | 0.030 |
Why?
| | Hematoxylin | 1 | 2013 | 3 | 0.030 |
Why?
| | Eosine Yellowish-(YS) | 1 | 2013 | 7 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2003 | 2330 | 0.030 |
Why?
| | Arginine | 1 | 2015 | 238 | 0.030 |
Why?
| | Fluoresceins | 1 | 2013 | 46 | 0.030 |
Why?
| | Constriction | 1 | 2013 | 46 | 0.030 |
Why?
| | CREB-Binding Protein | 1 | 2013 | 27 | 0.030 |
Why?
| | Movement | 1 | 2016 | 246 | 0.030 |
Why?
| | Chalcones | 1 | 2013 | 9 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 958 | 0.030 |
Why?
| | Ligation | 1 | 2013 | 76 | 0.030 |
Why?
| | Apamin | 2 | 2004 | 6 | 0.030 |
Why?
| | Mice, Inbred C3H | 1 | 2013 | 242 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1436 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 213 | 0.030 |
Why?
| | Fluorescein-5-isothiocyanate | 1 | 2012 | 37 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 1816 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2001 | 1477 | 0.030 |
Why?
| | Fibronectins | 1 | 2012 | 108 | 0.020 |
Why?
| | Kidney Glomerulus | 1 | 2012 | 101 | 0.020 |
Why?
| | Proteins | 1 | 1997 | 915 | 0.020 |
Why?
| | Comorbidity | 1 | 2016 | 1458 | 0.020 |
Why?
| | Lymphocyte Subsets | 1 | 2011 | 79 | 0.020 |
Why?
| | Receptors, CCR7 | 1 | 2011 | 24 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 1841 | 0.020 |
Why?
| | Receptors, CCR5 | 1 | 2011 | 54 | 0.020 |
Why?
| | Hyaluronan Receptors | 1 | 2011 | 91 | 0.020 |
Why?
| | Mice, SCID | 1 | 2011 | 319 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2018 | 2192 | 0.020 |
Why?
| | Blood | 1 | 2011 | 97 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2010 | 84 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2012 | 300 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 387 | 0.020 |
Why?
| | Aromatase | 1 | 2010 | 31 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2011 | 394 | 0.020 |
Why?
| | Kidney Cortex | 1 | 2010 | 23 | 0.020 |
Why?
| | Aromatase Inhibitors | 1 | 2010 | 49 | 0.020 |
Why?
| | Blood Urea Nitrogen | 1 | 2010 | 51 | 0.020 |
Why?
| | Renal Circulation | 1 | 2010 | 53 | 0.020 |
Why?
| | Acute-Phase Proteins | 1 | 2010 | 64 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 818 | 0.020 |
Why?
| | Lipocalins | 1 | 2010 | 35 | 0.020 |
Why?
| | Lipocalin-2 | 1 | 2010 | 62 | 0.020 |
Why?
| | Exploratory Behavior | 1 | 2010 | 84 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2013 | 451 | 0.020 |
Why?
| | Oncogene Proteins | 1 | 2010 | 53 | 0.020 |
Why?
| | Estrogen Receptor beta | 1 | 2010 | 35 | 0.020 |
Why?
| | Castration | 1 | 2009 | 14 | 0.020 |
Why?
| | Blood Chemical Analysis | 1 | 2010 | 90 | 0.020 |
Why?
| | Androgen Receptor Antagonists | 1 | 2009 | 30 | 0.020 |
Why?
| | Middle Aged | 2 | 2021 | 26873 | 0.020 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2010 | 198 | 0.020 |
Why?
| | Androgen Antagonists | 1 | 2009 | 69 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4430 | 0.020 |
Why?
| | Creatinine | 1 | 2010 | 428 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1138 | 0.020 |
Why?
| | Wound Healing | 1 | 2010 | 259 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2011 | 1084 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 676 | 0.020 |
Why?
| | Pediatrics | 1 | 2013 | 986 | 0.020 |
Why?
| | Autoimmunity | 1 | 2011 | 818 | 0.020 |
Why?
| | Infant | 1 | 2018 | 7966 | 0.020 |
Why?
| | Young Adult | 1 | 2021 | 10520 | 0.020 |
Why?
| | Child, Preschool | 1 | 2018 | 9124 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2004 | 292 | 0.010 |
Why?
| | Evoked Potentials | 1 | 2004 | 108 | 0.010 |
Why?
| | Blood Pressure | 1 | 2010 | 1540 | 0.010 |
Why?
| | Intracellular Membranes | 1 | 2003 | 73 | 0.010 |
Why?
| | COS Cells | 1 | 2003 | 175 | 0.010 |
Why?
| | Myoblasts | 1 | 2003 | 77 | 0.010 |
Why?
| | Genes, Reporter | 1 | 2003 | 257 | 0.010 |
Why?
| | Enhancer Elements, Genetic | 1 | 2003 | 152 | 0.010 |
Why?
| | Muscle Denervation | 1 | 2001 | 9 | 0.010 |
Why?
| | Egtazic Acid | 1 | 2001 | 44 | 0.010 |
Why?
| | Sarcoplasmic Reticulum | 1 | 2001 | 43 | 0.010 |
Why?
| | Cobalt | 1 | 2001 | 46 | 0.010 |
Why?
| | Chelating Agents | 1 | 2001 | 65 | 0.010 |
Why?
| | Potassium | 1 | 2001 | 128 | 0.010 |
Why?
| | Calcium Channels | 1 | 2001 | 146 | 0.010 |
Why?
| | Base Sequence | 1 | 2003 | 2120 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2797 | 0.010 |
Why?
| | Biotransformation | 1 | 1997 | 50 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2003 | 1317 | 0.010 |
Why?
| | Leptin | 1 | 1997 | 212 | 0.010 |
Why?
| | Potassium Channel Blockers | 1 | 1996 | 29 | 0.010 |
Why?
| | Xenopus laevis | 1 | 1996 | 118 | 0.010 |
Why?
| | Macromolecular Substances | 1 | 1996 | 200 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1996 | 317 | 0.010 |
Why?
| | Oocytes | 1 | 1996 | 171 | 0.010 |
Why?
| | DNA Primers | 1 | 1996 | 515 | 0.010 |
Why?
|
|
Herson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|